Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen

被引：12
|
作者：
Ferraldeschi, Roberta [1 ,2 ]
Howell, Sacha J. [1 ]
Thompson, Alastair M. [3 ,4 ]
Newman, William G. [5 ]
机构：
[1] Christie Hosp Natl Hlth Serv Fdn Trust, Manchester, Lancs, England
[2] Univ Manchester, St Marys Hosp, Manchester Acad Hlth Sci Ctr MAHSC, Manchester M13 0JH, Lancs, England
[3] Univ Dundee, Dundee, Scotland
[4] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Manchester, Manchester Acad Hlth Sci Ctr MAHSC, Manchester, Lancs, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 29期
关键词：
CANCER RECURRENCE RISK; ANTIDEPRESSANT USE; METABOLISM; GENOTYPE; WOMEN;
D O I：
10.1200/JCO.2010.30.1887
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：E584 / E585
页数：2
相关论文
共 50 条
  • [21] Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment
    Xu, Y.
    Sun, Y.
    Yao, L.
    Shi, L.
    Wu, Y.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    He, L.
    Li, P.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2008, 19 (08) : 1423 - 1429
  • [22] Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    Laurent Azoulay
    Sophie Dell’Aniello
    Laetitia Huiart
    Guillaume Galbaud du Fort
    Samy Suissa
    Breast Cancer Research and Treatment, 2011, 126 : 695 - 703
  • [23] Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
    Azoulay, Laurent
    Dell'Aniello, Sophie
    Huiart, Laetitia
    du Fort, Guillaume Galbaud
    Suissa, Samy
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (03) : 695 - 703
  • [24] Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors
    Aubert, R. E.
    Stanek, E. J.
    Yao, J.
    Teagarden, J. R.
    Subar, M.
    Epstein, R. S.
    Skaar, T. C.
    Desta, Z.
    Flockhart, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [25] CYP2D6 and CYP3A influence tamoxifen and endoxifen
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (05) : 524 - 525
  • [26] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [27] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [28] A novel CYP2D6 scoring system for the prediction of CYP2D6 activity: Application to tamoxifen metabolism.
    Borges, S.
    Li, L.
    Robarge, J.
    Nguyen, A.
    Azzouz, F.
    Desta, Z.
    Skaar, T.
    Flockhart, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S67 - S67
  • [29] Tamoxifen Resistance and CYP2D6 Copy Numbers in Breast Cancer Patients
    Motamedi, Sahar
    Majidzadeh, Keivan
    Mazaheri, Mahta
    Anbiaie, Robab
    Mortazavizadeh, Seyed Mohammad Reza
    Esmaeili, Rezvan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (12) : 6101 - 6104
  • [30] The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity
    Welzen, Marieke E. B.
    Dezentje, Vincent O.
    van Schaik, Ron H. N.
    Colbers, Angela P. H.
    Guchelaar, Henk-Jan
    van Erp, Nielka P.
    den Hartigh, Jan
    Burger, David M.
    van Laarhoven, Hanneke W. M.
    THERAPEUTIC DRUG MONITORING, 2015, 37 (04) : 501 - 507
12345